SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD

4.360

-0.050 (-1.13%)

At close: Apr 23, 2024, 11:50 AM

4.490

+0.130 (2.98%)

After-hours: Apr 23, 2024, 4:00 PM EDT

SAB Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	2.24	23.9	60.88	55.24	3.44
Revenue Growth (YoY)	-90.63%	-60.73%	10.21%	1504.91%	-
Gross Profit	2.24	23.9	60.88	55.24	3.44
Selling, General & Admin	23.8	16.38	17.09	6.77	4.1
Research & Development	16.52	36.44	57.18	27.91	8.02
Operating Expenses	40.31	52.82	74.27	34.68	12.12
Operating Income	-38.08	-28.92	-13.39	20.56	-8.67
Interest Expense / Income	0.32	0.3	0.29	0.47	0.43
Other Expense / Income	3.8	-10.5	3.46	-0.03	-0.12
Pretax Income	-42.19	-18.72	-17.14	20.12	-8.99
Income Tax	0	0.03	0	0	0
Net Income	-42.19	-18.74	-17.14	20.12	-8.99
Shares Outstanding (Basic)	6	4	3	3	4
Shares Outstanding (Diluted)	6	4	3	3	4
Shares Change	26.86%	59.20%	1.21%	-23.30%	-
EPS (Basic)	-7.64	-4.31	-6.30	7.90	-2.60
EPS (Diluted)	-7.64	-4.31	-6.30	7.40	-2.60
Free Cash Flow	-25.27	-25.55	-8.96	-2.72	-9.82
Free Cash Flow Per Share	-4.58	-5.87	-3.28	-1.07	-2.79
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1700.56%	-120.97%	-22.00%	37.22%	-252.01%
Profit Margin	-1884.50%	-78.40%	-28.16%	36.42%	-261.09%
Free Cash Flow Margin	-1128.73%	-106.88%	-14.71%	-4.92%	-285.41%
EBITDA	-38.13	-15.12	-15.2	21.14	-8.23
EBITDA Margin	-1703.14%	-63.26%	-24.96%	38.26%	-239.25%
Depreciation & Amortization	3.75	3.29	1.65	0.55	0.32
EBIT	-41.88	-18.41	-16.85	20.59	-8.56
EBIT Margin	-1870.42%	-77.03%	-27.68%	37.27%	-248.64%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).